The development of effective tuberculosis vaccines faces persistent challenges linked to the natural course of Mycobacterium tuberculosis (M.tb) infection. Investigators note that most individuals infected with M.tb do not rapidly progress to active disease, necessitating very large and extended clinical trials to accumulate enough disease endpoints. Currently, trials commonly enroll participants based on a positive Interferon-Gamma Release Assay (IGRA), which detects M.tb infection but remains positive for years, failing to discriminate newly infected individuals from those infected in the remote past. This limitation hampers recruitment efficiency, prompting research into diagnostics that can identify recent M.tb infection. Such tools might enable faster, more focused vaccine trials by selectively enrolling those at higher risk of progression.
Researchers applied a statistical modeling framework to evaluate how screening for recent M.tb infection could affect enrollment needs in vaccine trials. They defined an effective trial as one accruing 50 disease endpoints and compared five recruitment strategies: non-test-based enrollment for ages 15-49 years, ages 12-34 years, household contacts of recent TB cases; IGRA-based enrollment; and enrollment using a novel test for recent infection exhibiting a two-year duration of positivity. The study modeled trial scenarios in high TB burden countries—South Africa, Kenya, and India—to capture varied epidemiological settings. The analysis focused on key metrics including the number needed to contact, test, and enroll to reach the endpoint target, estimating both efficiency and resource implications.
The modeling results revealed that a test detecting recent M.tb infection reduced the median number of participants needed to enroll by approximately 4.2 to 6-fold compared to traditional IGRA gating, assuming optimistic testing conditions. Notably, this recency-based approach also outperformed recruitment strategies that did not use diagnostics, including enrolling household contacts, who are at elevated risk but less selectively targeted. These gains signify that identifying recent infections can concentrate the trial cohort on individuals more likely to progress to disease during follow-up, thereby reducing sample size requirements and potentially shortening trial duration. However, the strategy entails substantially increased testing volume due to the need to screen larger populations to detect sufficient recent infections.
Balancing the benefits and costs of recency testing is complex. While the increased testing volume imposes higher upfront expenditures, the investigators estimated that overall vaccine trial costs could decline provided that the new recency test does not exceed approximately 5 to 10 times the cost of an IGRA. This cost threshold reflects a trade-off between test expense and enrollment efficiency. The analysis underscores that economic viability hinges on the pricing and operational characteristics of the novel diagnostic. Targeted health economic studies are necessary to validate these preliminary cost estimates under diverse real-world conditions.
Before integrating recency diagnostics into vaccine trials, critical performance criteria must be characterized. These include the time from infection to test positivity, the persistence or duration of positivity following infection, as well as the test’s sensitivity and specificity. Such attributes influence both the accuracy of identifying recently infected individuals and the capacity to enrich trial populations without excluding eligible candidates. The authors emphasize the need for further research to establish these parameters robustly, enabling reliable application in clinical trial design.
The study acknowledges that conclusions are drawn from a statistical model reliant on assumptions about infection dynamics and diagnostic test properties that have not yet been fully empirically validated. Key uncertainties remain regarding the real-world performance of tests for recent M.tb infection and their operational feasibility in diverse settings. Moreover, the analysis does not incorporate details on dosing strategies or specific vaccine candidates. The findings highlight the necessity for prospective studies to assess test attributes, alongside pilot evaluations of recency-based enrollment strategies in ongoing vaccine trials. Further investigation is also required to address ethical and logistical considerations when implementing such diagnostics in target populations.